Program
obudanersen sodium
Also written as “obudanersen” and “ION582”.
Its studies are mostly in Angelman Syndrome, led by Ionis Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ionis Pharmaceuticals | 33 open or running | phase 3since Mar 22, 2025 | Nov 9, 2021 | Aug 2027phase 3 · NCT06914609 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2021First study: phase 2 study in Angelman SyndromeFirst studyNCT05127226 · 71 enrolled · United States, Australia, France and more
- Mar 22, 2025Phase 3 study in Angelman SyndromeNCT06914609 · 156 enrolled · United States, Australia, Canada and more
- Aug 20, 2026Phase 3 study in Angelman SyndromeNCT07782827 · 30 planned · United States
- Nov 17, 2026Primary completion moved from 2029-03 to 2032-03Date moved laterphase 2 · +36 months · NCT05127226
Ahead
- Aug 2027Primary completion: phase 3 study in Angelman SyndromeNCT06914609
- May 2028Primary completion: phase 3 study in Angelman SyndromeNCT07782827
- Mar 2032Primary completion: phase 2 study in Angelman SyndromeNCT05127226
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07782827Angelman Syndrome · United States | 3 | Recruiting | May 2028 | 30 |
| NCT06914609Angelman Syndrome · United States, Australia, Canada and more | 3 | Active, not recruiting | Aug 2027 | 156 |
| NCT05127226Angelman Syndrome · United States, Australia, France and more | 2 | Active, not recruiting | Mar 2032 | 71 |
How it is read
Names in the registry
- “obudanersen”, 2 entries
- “ION582”, 1 entry
Conditions, from the studies’ own filings
- Angelman Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.